Ingredient: L-Glutamine

L-glutamine is a naturally occurring amino acid found in dietary protein and studied in humans as free L-glutamine, pharmaceutical oral powder, enteral nutrition, parenteral nutrition, and glutamine-containing dipeptide formulations such as L-alanyl-L-glutamine (Research).

L-glutamine has been studied in Digestive and Gastrointestinal Health, Blood Health, Cancer Research, Beauty and Skin Health, Muscle Health, and Immune System contexts, but the maturity of evidence differs substantially by condition and formulation (Research) (Research). The strongest defined clinical evidence is in Blood Health for sickle cell disease, where FDA approved L-glutamine oral powder after clinical review of the product-specific evidence base (FDA). Digestive and Gastrointestinal Health and Cancer Research evidence includes randomized trials and meta-analyses, while critical-illness, burn, and exercise-recovery findings are more mixed or limited (Review) (Review) (Review).

Ingredient Identity

• Official name(s): L-glutamine.
• Synonyms: Glutamine; L-2-aminoglutaramic acid.
• Classification: Amino acid studied in dietary, supplemental, clinical-nutrition, pharmacokinetic, and pharmaceutical contexts (Research).
• CAS number: 56-85-9.
• Endogenous vs exogenous: The locked human evidence base includes dietary protein exposure, isolated oral L-glutamine, enteral glutamine, parenteral glutamine dipeptide nutrition, IV L-alanyl-L-glutamine, and FDA-reviewed L-glutamine oral powder (Research) (Research) (FDA).
• Related researched forms: L-alanyl-L-glutamine, also written L-alanylglutamine or AlaGln, is a glutamine-containing dipeptide studied as a delivery form that can raise plasma L-glutamine differently from free L-glutamine or hydrolyzed protein forms (Research).
• Formulation distinction: Free L-glutamine, L-alanyl-L-glutamine, hydrolyzed protein, enteral glutamine, IV dipeptide delivery, parenteral nutrition, and pharmaceutical oral powder are distinct glutamine-delivery contexts and should not be treated as interchangeable (Research) (Research).

Ingredient Snapshot

• Classification: L-glutamine is an amino acid studied as dietary exposure, isolated oral dosing, clinical nutrition, pharmacokinetic exposure, and pharmaceutical oral powder (Research) (FDA).
• Endogenous vs exogenous status: Human research measures L-glutamine exposure through diet-derived intake, controlled protein intake, oral free L-glutamine, glutamine-containing dipeptides, enteral administration, and parenteral nutrition contexts (Research) (Research) (Research).
• Primary human research domains: The main SHIZAM research domains supported by the locked evidence base are Digestive and Gastrointestinal Health, Blood Health, Cancer Research, Beauty and Skin Health, Muscle Health, and Immune System (Research) (Research) (Review).
• Common study formats: The evidence base includes randomized controlled trials, randomized crossover exercise studies, pharmacokinetic studies, dietary cohort analyses, and systematic reviews or meta-analyses (Research) (Research) (Review).
• Pharmacokinetic characterization status: Human studies have measured plasma L-glutamine response after free L-glutamine, L-alanylglutamine, hydrolyzed wheat protein, enteral glutamine, and oral dose-ascending L-glutamine exposure (Research) (Research).
• Regulatory context, U.S./EU: FDA approved L-glutamine oral powder for reducing acute complications of sickle cell disease in adults and pediatric patients 5 years and older (FDA). EMA lists Xyndari, a glutamine medicine application for sickle cell disease, as withdrawn (EMA).
• Evidence maturity: Overall evidence is Moderate / Mixed because sickle cell disease has defined regulatory and randomized-trial support, while gastrointestinal, mucositis, burn, critical-illness, and exercise findings vary by population, dose, formulation, and endpoint (Research) (Review).

Introduction

L-glutamine is an amino acid present in dietary protein and studied in humans across ordinary dietary exposure, controlled dietary protein intake, oral supplementation, enteral nutrition, parenteral nutrition, and pharmaceutical oral powder contexts (Research) (Research) (FDA). Human absorption research also distinguishes free L-glutamine from glutamine-containing formulations such as L-alanylglutamine and hydrolyzed wheat protein because these formats can produce different plasma L-glutamine response patterns (Research).

People look up L-glutamine because human studies have examined IBS-D, intestinal permeability, sickle cell disease complications, oral mucositis during cancer therapy, burn-related infection outcomes, critical-illness nutrition, and exercise recovery (Research) (Research) (Research). The evidence has attracted interest because L-glutamine appears in both nutrition science and clinical medicine, but results depend heavily on whether the study used dietary exposure, free oral L-glutamine, a glutamine-containing dipeptide, enteral delivery, IV delivery, or an FDA-reviewed pharmaceutical formulation (Research) (Review).

This article is informational only, describes L-glutamine as a biochemical substance studied in human research, and does not provide medical or dosing advice.

Quick Summary

• L-glutamine is an amino acid studied in humans as dietary exposure, free oral L-glutamine, clinical nutrition, glutamine-containing dipeptides, and FDA-reviewed pharmaceutical oral powder (Research) (FDA).
• The strongest defined human evidence is in Blood Health for sickle cell disease, where FDA approved L-glutamine oral powder for reducing acute complications in adults and pediatric patients 5 years and older (Research) (FDA).
• Digestive and Gastrointestinal Health evidence includes randomized IBS trials and a systematic review/meta-analysis on intestinal permeability, but findings are specific to studied populations and protocols (Research) (Review).
• Cancer Research evidence mainly concerns oral mucositis, dysphagia, stomatitis, and treatment-related supportive-care outcomes during chemotherapy or radiotherapy, not direct cancer treatment (Review) (Research).
• L-alanyl-L-glutamine is a glutamine-containing dipeptide, not the same molecule as free L-glutamine, and human absorption research shows formulation-dependent plasma L-glutamine responses (Research).
• Critical-illness and burn evidence is mixed because individual trials may report infection-related signals while systematic reviews caution against routine use across broad hospitalized populations (Research) (Review) (Review).
• Muscle Health evidence is limited because the locked evidence base includes a small short-term randomized crossover trial after eccentric exercise rather than broad long-term performance evidence (Research).

Human Research Findings by Condition

Digestive and Gastrointestinal Health

Human research on Digestive and Gastrointestinal Health includes randomized IBS trials, intestinal-permeability synthesis, jejunal absorption research, and clinical-nutrition studies involving intestinal absorption capacity (Research) (Review) (Research). The most directly applicable clinical evidence comes from defined IBS populations, while absorption and critical-illness studies provide physiological or hospital-nutrition context rather than broad digestive-health claims (Research) (Research).

Key human study

Dose studied: 15 g/day
Population: Adults with post-infectious IBS-D and increased intestinal permeability
Duration: 8 weeks

Researchers studied oral glutamine in post-infectious IBS-D with increased intestinal permeability and evaluated IBS symptom severity and permeability-related outcomes (Research). The randomized, double-blind, placebo-controlled design makes this a directly relevant Digestive and Gastrointestinal Health trial for free oral L-glutamine in a defined IBS-D subgroup (Research). The result should be interpreted within the studied population because it does not establish a universal effect across all IBS or digestive conditions (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: 15 g/day
Population: Adults with IBS using a low-FODMAP diet context
Duration: 6 weeks

A randomized trial studied glutamine as an addition to a low-FODMAP diet and reported greater IBS symptom improvement than low-FODMAP diet alone (Research). This study supports a Digestive and Gastrointestinal Health signal, but the finding is specific to a combination protocol rather than isolated glutamine in every IBS setting (Research). The trial is useful for article interpretation because it shows that diet context can materially affect how glutamine evidence should be read (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Blood Health

Blood Health is the most clinically defined evidence area for L-glutamine because sickle cell disease has randomized trial evidence and an FDA-approved product-specific oral powder context (Research) (FDA). This evidence should be described as sickle-cell-specific and pharmaceutical-formulation-specific rather than generalized to all blood-health outcomes (FDA).

Key human study

Dose studied: 0.3 g/kg per dose twice daily
Population: Children and adults with sickle cell anemia or sickle β0-thalassemia
Duration: 48 weeks

A phase 3 randomized trial studied pharmaceutical-grade L-glutamine in sickle cell disease and evaluated acute complications including pain crises and hospitalizations (Research). The study provides condition-specific clinical evidence for L-glutamine in sickle cell disease rather than general evidence for unrelated blood-health outcomes (Research). FDA approval of L-glutamine oral powder was for reducing acute complications of sickle cell disease in adults and pediatric patients 5 years and older (FDA).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Strong
Study source: (Research)

Additional human study

Dose studied: L-glutamine with stable hydroxyurea context
Population: Children with sickle cell disease receiving stable hydroxyurea
Duration: Reported in the trial publication

A 2024 randomized trial studied L-glutamine in pediatric sickle cell disease patients receiving stable hydroxyurea and reported reduced vaso-occlusive crises and possible favorable effects on cerebral arterial flow velocities (Research). This trial adds pediatric combination-treatment context, but it should not be interpreted as a broad interaction claim or as evidence for all sickle cell treatment backgrounds (Research). The evidence supports Blood Health relevance only within the disease-specific and treatment-context boundaries of the study (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Cancer Research

Cancer Research evidence for L-glutamine is mainly supportive-care evidence involving oral mucositis, dysphagia, stomatitis, and treatment-related toxicity during chemotherapy or radiotherapy (Review) (Review). These studies should not be described as evidence that L-glutamine treats cancer because the locked evidence concerns treatment-related adverse effects and supportive-care outcomes (Research).

Key human study

Dose studied: 10 g oral glutamine before radiotherapy on treatment days
Population: Patients with oropharynx and larynx carcinoma receiving chemoradiotherapy
Duration: 7-week treatment course

A randomized controlled trial administered 10 g oral glutamine before radiotherapy on treatment days in patients with oropharynx and larynx carcinoma receiving chemoradiotherapy (Research). The study reported lower incidence and severity of oral mucositis and dysphagia in the studied supportive-care setting (Research). The result is relevant to Cancer Research as oncology supportive care, not as direct anticancer efficacy evidence (Research).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: IV L-alanyl-L-glutamine as reported in the trial
Population: Patients with head and neck cancer receiving chemoradiotherapy
Duration: During chemoradiotherapy period

A double-blind placebo-controlled trial studied intravenous L-alanyl-L-glutamine and chemoradiotherapy-associated oral mucositis in head and neck cancer (Research). L-alanyl-L-glutamine is a glutamine-containing dipeptide delivery form, so this finding should not be treated as identical to oral free L-glutamine evidence (Research). The trial is relevant to supportive-care mucositis outcomes in a specific oncology-treatment setting (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Beauty and Skin Health

Beauty and Skin Health evidence for L-glutamine comes from burn-injury research rather than cosmetic skin research (Research). Burn studies and reviews evaluate infection, bacteremia, wound-care, hospitalization, and clinical-nutrition outcomes rather than skin appearance or aesthetic endpoints (Research) (Review).

Key human study

Dose studied: Glutamine supplementation as reported in the burn trial
Population: Severely burned patients
Duration: Acute burn-care period

A prospective randomized double-blind trial studied glutamine in severely burned patients and reported reduced gram-negative bacteremia (Research). This is relevant to Beauty and Skin Health only through severe skin-injury and burn-care physiology, not cosmetic or appearance-based claims (Research). The study contributes to burn-care evidence but should be interpreted alongside systematic reviews that are more cautious about routine burn supplementation (Review).

Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Moderate
Study source: (Research)

Additional human study

Dose studied: Enteral glutamine supplementation as reported in the clinical study
Population: Adult burn patients
Duration: Burn-care treatment period

A clinical study in adult burn patients reported reduced blood infection and bacteremia outcomes with enteral glutamine supplementation (Research). This adds a second burn-care context but remains specific to hospitalized burn patients and clinical nutrition rather than general skin wellness (Research). The finding should be balanced with later review-level evidence that did not recommend routine glutamine supplementation for hospitalized burn patients based on available data (Review).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Muscle Health

Muscle Health evidence is limited compared with the sickle cell disease, IBS, mucositis, and clinical-nutrition evidence areas (Research). The locked evidence base supports only a narrow short-term exercise-recovery context after eccentric exercise, not broad claims about strength, hypertrophy, endurance, or athletic performance (Research).

Key human study

Dose studied: 0.3 g/kg/day
Population: Sixteen healthy adults after eccentric exercise
Duration: 72-hour recovery period

A randomized placebo-controlled crossover study evaluated oral L-glutamine during recovery after eccentric exercise (Research). The study reported faster peak-torque recovery and lower soreness ratings over 72 hours, but the evidence is narrow because it involved a small sample and a short recovery window (Research). The study is best described as preliminary Muscle Health recovery evidence rather than evidence for long-term training outcomes (Research).

Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)

Immune System

Immune System evidence is indirect and context-specific because the locked human sources usually assess infection, bacteremia, critical illness, burns, or clinical nutrition rather than everyday immune enhancement (Research) (Review). Systematic reviews in critical illness are cautionary because they do not support routine glutamine addition across all critically ill patients for hospital mortality reduction (Review).

Key human study

Dose studied: Glutamine supplementation across critical-illness trials
Population: Critically ill patients
Duration: Varied across included studies

A systematic review and meta-analysis evaluated glutamine supplementation in critically ill patients and concluded that it should not be routinely added to critical-illness diets to reduce hospital mortality (Review). This source is relevant to Immune System interpretation because critical illness studies often evaluate infection, stress physiology, and clinical outcomes, but it does not support broad routine-use claims (Review). The result shows that biological plausibility and individual trial signals do not automatically translate into consistent clinical benefit across heterogeneous critical-care populations (Review).

Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Review)

Additional human study

Dose studied: Enteral glutamine supplementation across included studies
Population: Critically ill patients
Duration: Varied across trials

A systematic review and meta-analysis evaluated enteral glutamine supplementation in critically ill patients and assessed clinical outcomes across trials (Review). This evidence is relevant to clinical-nutrition and immune-stress contexts but depends on route, baseline illness severity, and study design (Review). The review supports a mixed and context-dependent interpretation rather than a general immune-system claim (Review).

Result: Human clinical studies reported mixed findings
Evidence strength: Mixed
Study source: (Review)

Dosage & Study Snapshot (Research Context)

Human L-glutamine exposure has been studied through dietary intake, controlled dietary protein intake, free oral L-glutamine, glutamine-containing dipeptides, enteral glutamine, IV L-alanyl-L-glutamine, parenteral nutrition, and FDA-reviewed pharmaceutical oral powder (Research) (Research) (FDA). Dietary exposure bands appear first because they represent ordinary food or protein-intake contexts, while isolated supplemental, clinical-nutrition, and pharmaceutical exposures represent more specific research or regulatory settings (Research).

Habitual dietary glutamine and glutamate intake:

Dietary exposure was estimated from food patterns rather than administered as isolated L-glutamine (Research). This cohort analysis evaluated dietary glutamine and glutamate intake in relation to cardiovascular disease incidence and mortality among adults with type 2 diabetes (Research). This is the lowest real-world exposure context in the locked citation library because it reflects ordinary dietary intake rather than a supplement, dipeptide, enteral, IV, or pharmaceutical dose (Research). The finding is observational, so it cannot establish that isolated L-glutamine caused the reported associations (Research).

Result: Observational association
Evidence strength: Observational
Notes / limitations: Dietary exposure findings should not be treated as isolated L-glutamine supplement-dose evidence.

0.1, 0.8, and 2.2 g/kg/day dietary protein exposure:

A controlled dietary study measured glutamine and glutamate kinetics after deficient, adequate, and high protein intakes of 0.1, 0.8, and 2.2 g/kg/day in healthy young men (Research). This study did not administer isolated L-glutamine, but it helps define how dietary protein context can affect glutamine-related kinetics (Research). The exposure belongs before isolated supplement bands because the source was dietary protein rather than free L-glutamine powder or pharmaceutical oral powder (Research). The small sample and kinetic focus mean this band is most useful for physiological context, not clinical outcome interpretation (Research).

Result: Human studies observed short-term physiological effects
Evidence strength: Limited
Notes / limitations: This dose band reflects dietary protein kinetics, not isolated L-glutamine supplementation.

60 mg/kg L-glutamine, 89 mg/kg L-alanylglutamine, and 200 mg/kg hydrolyzed wheat protein:

A human absorption study compared 60 mg/kg free L-glutamine, 89 mg/kg L-alanylglutamine, 200 mg/kg hydrolyzed wheat protein, and water control in healthy men (Research). Plasma L-glutamine rose after all active formats, but peak timing and exposure differed by formulation (Research). L-alanylglutamine, also called L-alanyl-L-glutamine or AlaGln, is a glutamine-containing dipeptide rather than free L-glutamine, so it should be interpreted as a delivery form rather than the same ingredient molecule (Research). This dose band is important because it shows that glutamine-containing formulations can produce different plasma response patterns even when they are all used to increase L-glutamine exposure (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Plasma response differences do not automatically predict clinical outcome differences.

Enterally administered glutamine with dose-dependent jejunal absorption:

A human intestinal absorption study found that enterally administered glutamine was efficiently absorbed by the human jejunum and produced a dose-dependent plasma glutamine rise (Research). This source is most useful for absorption and gastrointestinal physiology rather than condition-specific clinical benefit (Research). The exposure differs from ordinary oral supplement use because the study examined enteral administration in a controlled absorption context (Research). The finding supports human intestinal uptake but does not by itself establish clinical benefit in IBS, critical illness, or other gastrointestinal conditions (Research).

Result: Human studies observed short-term physiological effects
Evidence strength: Emerging
Notes / limitations: This is absorption evidence, not a clinical outcome trial.

0.1 and 0.3 g/kg twice daily, and 0.6 g/kg once daily:

A dose-ascending pharmacokinetic study examined oral L-glutamine at 0.1 g/kg twice daily, 0.3 g/kg twice daily, and 0.6 g/kg once daily in pediatric and adult participants with sickle cell disease and adult healthy volunteers (Research). The study measured plasma exposure across ascending oral dose levels over three weeks (Research). A related PK/PD study measured pharmacokinetic exposure and peak concentration to evaluate pharmacodynamic response markers in a sickle cell disease research context (Research). These sources are useful for dose-exposure interpretation, but they should not be treated as broad clinical efficacy evidence outside their pharmacokinetic and pharmacodynamic designs (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: PK and PK/PD evidence can inform exposure but does not replace clinical outcome trials.

0.3 g/kg/day oral L-glutamine:

A randomized placebo-controlled crossover exercise study used 0.3 g/kg/day oral L-glutamine during a 72-hour recovery period after eccentric exercise (Research). The study reported faster peak-torque recovery and lower soreness ratings over 72 hours in the studied short-term recovery context (Research). This dose band is relevant to Muscle Health but does not establish long-term performance, hypertrophy, or endurance effects (Research). The sample size and duration make the evidence limited despite the randomized crossover design (Research).

Result: Modest improvement
Evidence strength: Limited
Notes / limitations: The population was small and the outcome window was short.

10 g oral glutamine before radiotherapy on treatment days:

A randomized controlled trial administered 10 g oral glutamine before radiotherapy five days per week during a seven-week chemoradiotherapy course (Research). The study population included patients with oropharynx and larynx carcinoma, and outcomes included oral mucositis and dysphagia (Research). This dose band is specific to oncology supportive care during radiation treatment rather than general Cancer Research or anticancer efficacy (Research). The dose and schedule should be interpreted only as a research protocol, not as medical or dosing advice (Research).

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: This context concerns treatment-related mucositis and dysphagia, not cancer control.

15 g/day oral glutamine:

A randomized IBS-D trial studied 15 g/day oral glutamine for eight weeks in adults with post-infectious IBS-D and increased intestinal permeability (Research). Another randomized trial studied 15 g/day glutamine added to a low-FODMAP diet for IBS symptoms (Research). This dose band is relevant to Digestive and Gastrointestinal Health, especially IBS-related symptom research and permeability-related study designs (Research). The two trials differ because one studied post-infectious IBS-D with permeability findings, while the other studied a diet-combination context (Research).

Result: Statistically significant improvement
Evidence strength: Moderate
Notes / limitations: The findings are specific to IBS populations and protocols.

20 g alanyl-glutamine dipeptide:

A pharmacokinetic study examined 20 g L-alanyl-L-glutamine dipeptide given by bolus or intermittent protocols (Research). The study found that pharmacokinetic response differed by dosing protocol, showing that timing and administration pattern can influence plasma glutamine exposure (Research). L-alanyl-L-glutamine is a glutamine-containing dipeptide delivery form, not free L-glutamine, so this band should be separated from free L-glutamine oral powder evidence (Research). This dose band informs formulation and PK interpretation rather than disease-specific clinical outcomes (Research).

Result: Preliminary signal
Evidence strength: Emerging
Notes / limitations: Dipeptide PK evidence should not be treated as identical to free L-glutamine clinical evidence.

10 g, 20 g, or 30 g/day FDA-reviewed oral powder dosing:

FDA clinical pharmacology materials describe body-weight-based total daily doses of 10 g, 20 g, or 30 g divided into two doses for L-glutamine oral powder in the Endari clinical-development and review context (FDA). FDA approved L-glutamine oral powder for reducing acute complications of sickle cell disease in adults and pediatric patients 5 years and older (FDA). This dose band is regulatory and disease-specific, not a general supplement-use recommendation (FDA). It should be separated from dietary protein, IBS research dosing, exercise-recovery dosing, and glutamine-containing dipeptide exposure because the product and indication are specific (FDA).

Result: Statistically significant improvement
Evidence strength: Strong
Notes / limitations: This is FDA-reviewed pharmaceutical dosing for a specific sickle cell disease indication.

Key Takeaways from Human Research

• Blood Health has the clearest human evidence because sickle cell disease trials and FDA review support a defined L-glutamine oral powder use case (Research) (FDA).
• Digestive and Gastrointestinal Health evidence includes IBS trials and intestinal-permeability synthesis, but findings should be interpreted by IBS subtype, diet context, permeability status, and protocol (Research) (Research) (Review).
• Cancer Research evidence is mainly supportive-care evidence for oral mucositis, dysphagia, or stomatitis during chemotherapy or radiotherapy, not direct cancer-treatment evidence (Review) (Research).
• Burn and critical-illness evidence is mixed because individual studies may report infection-related signals while systematic reviews caution against broad routine use in hospitalized or critically ill populations (Research) (Review) (Review).
• Absorption and PK evidence show that formulation, route, dose, and dosing pattern affect plasma L-glutamine response, especially when comparing free L-glutamine with L-alanyl-L-glutamine or protein-derived glutamine (Research) (Research).
• Muscle Health evidence remains limited because the locked evidence includes a small short-term exercise-recovery trial rather than broad long-term athletic-performance research (Research).

Origin & Natural Occurrence

L-glutamine occurs in dietary protein, and human nutrition studies have measured glutamine-related exposure through ordinary food-intake patterns or controlled dietary protein protocols (Research) (Research). Dietary exposure differs from isolated L-glutamine powder because foods contain complex mixtures of amino acids and other nutrients rather than one isolated amino acid (Research).

Manufactured or research forms include free L-glutamine, L-alanyl-L-glutamine, hydrolyzed protein sources, enteral glutamine, IV L-alanyl-L-glutamine, parenteral glutamine dipeptide nutrition, and FDA-reviewed L-glutamine oral powder (Research) (Research) (FDA). These forms differ in exposure route, plasma response, study population, and regulatory context, so they should be described as distinct glutamine-containing formulations or delivery contexts rather than one interchangeable family (Research) (Research).

How It Behaves in the Body

In simple terms, L-glutamine can be absorbed from the gut and measured in the bloodstream after oral or enteral exposure (Research). Human absorption research shows that plasma L-glutamine can rise after free L-glutamine, L-alanylglutamine, and hydrolyzed wheat protein, but the response pattern differs by formulation (Research).

A key distinction is that free L-glutamine is a single amino acid, while L-alanyl-L-glutamine is a dipeptide made from alanine and glutamine and used as a glutamine-containing delivery form in research (Research). Because the dipeptide must be interpreted as a delivery format, findings from L-alanyl-L-glutamine studies should not automatically be treated as identical to findings from free oral L-glutamine studies (Research).

Pharmacokinetic research in sickle cell disease studied oral L-glutamine across ascending weight-based doses and measured exposure and peak-concentration-related outcomes (Research). A related PK/PD study measured pharmacokinetic exposure and Cmax to evaluate pharmacodynamic response markers in a sickle cell disease research context (Research).

Clinical-nutrition studies show that glutamine can also be delivered through enteral or parenteral contexts, including jejunal administration and glutamine dipeptide-supplemented parenteral nutrition (Research) (Research). These delivery contexts help explain body handling of glutamine, but they should not be treated as interchangeable with ordinary dietary intake or common free L-glutamine oral exposure (Research).

What is relatively well characterized is that L-glutamine exposure can be measured through plasma response after oral, enteral, dipeptide, or clinical-nutrition delivery formats (Research) (Research). What remains less certain is how consistently those exposure changes translate into clinical outcomes across unrelated conditions such as IBS, sickle cell disease, oral mucositis, burns, critical illness, and exercise recovery (Review) (Research).

Absorption & Delivery Formats

Oral immediate-release: Oral free L-glutamine has been studied in IBS-D, sickle cell disease, exercise recovery, and oncology supportive-care contexts (Research) (Research) (Research). Human PK research also evaluated ascending oral L-glutamine doses and plasma exposure measures in sickle cell disease and healthy-volunteer contexts (Research).

Oral extended-release: The locked citation library does not include verified human extended-release L-glutamine evidence. No extended-release conclusion should be made from the current locked evidence base.

Sublingual: The locked citation library does not include verified human sublingual L-glutamine studies. Sublingual absorption claims are therefore unsupported by the locked sources.

Transdermal: The locked citation library does not include verified human transdermal L-glutamine studies. Transdermal delivery claims are therefore unsupported by the locked sources.

Injectable / IV: IV L-alanyl-L-glutamine has been studied in a double-blind placebo-controlled mucositis trial during chemoradiotherapy in head and neck cancer (Research). L-alanyl-L-glutamine is a glutamine-containing dipeptide, so IV dipeptide evidence should be separated from oral free L-glutamine evidence (Research).

Parenteral nutrition: Glutamine dipeptide-supplemented parenteral nutrition has been studied in critical illness and small-intestinal absorption capacity contexts (Research). This is a clinical-nutrition route and should not be interpreted as ordinary dietary or oral supplement exposure (Research).

Enteral: Enterally administered glutamine was studied in human jejunal absorption research and showed efficient absorption in that controlled context (Research). Enteral glutamine has also been evaluated in critically ill patients through systematic review evidence, where findings depend on clinical context and outcome selection (Review).

Glutamine-containing dipeptides: L-alanyl-L-glutamine and L-alanylglutamine are dipeptide delivery forms that can increase plasma L-glutamine but should not be equated with free L-glutamine as a molecule (Research). A pharmacokinetic study of 20 g L-alanyl-L-glutamine found that bolus versus intermittent administration produced different pharmacokinetic responses (Research).

Quick Facts at a Glance

Onset reported: Plasma L-glutamine can rise after oral or enteral administration in human absorption studies (Research) (Research). Clinical outcome studies usually measured effects over days, weeks, or treatment courses rather than immediate onset windows (Research) (Research).

Time to peak (Tmax): Human absorption research reported that peak timing differed among free L-glutamine, L-alanylglutamine, and hydrolyzed wheat protein (Research). PK research in sickle cell disease measured exposure and peak-concentration-related parameters across oral dose levels, but those data should be interpreted within the studied population and dosing protocol (Research).

Half-life (t½): The locked evidence supports discussion of plasma exposure and PK parameters but does not support one universal half-life for all populations, routes, or glutamine-containing formulations (Research). Any half-life interpretation should remain tied to the specific PK study, dose, formulation, and population rather than generalized across all L-glutamine uses (Research).

Typical duration: IBS trials lasted 6 to 8 weeks, while the pivotal sickle cell disease trial lasted 48 weeks (Research) (Research). Exercise recovery was studied over 72 hours, and oncology supportive-care studies followed treatment-course timelines such as chemoradiotherapy periods (Research) (Research).

Absorption routes studied: Oral, enteral, IV dipeptide, and parenteral nutrition delivery formats are represented in the locked evidence library (Research) (Research) (Research). Sublingual, transdermal, and extended-release formats are not represented in the locked evidence library.

Formulation differences: Free L-glutamine, L-alanylglutamine, and hydrolyzed wheat protein produced different plasma L-glutamine response patterns in healthy men (Research). Bolus versus intermittent L-alanyl-L-glutamine also produced different pharmacokinetic responses, showing that dosing pattern can matter for glutamine-containing dipeptide exposure (Research).

Variability drivers: Variability may reflect route, formulation, dose, disease state, population, and outcome selection, as shown by differences across PK, IBS, sickle cell disease, oncology, critical-care, and burn evidence (Research) (Review). Critical illness is especially variable because pooled evidence differs across route, severity, and study design (Review).

Tolerance / adaptation: The locked evidence library does not establish a clear tolerance pattern for L-glutamine as a diminishing-response phenomenon. FDA and trial documents provide safety, dosing, and efficacy context for sickle cell disease rather than evidence of pharmacologic tolerance (FDA).

Evidence strength snapshot: Evidence is strongest for Blood Health in sickle cell disease, moderate or context-specific for Digestive and Gastrointestinal Health and Cancer Research supportive care, mixed in critical illness and burns, and limited in Muscle Health exercise recovery (Research) (Review) (Review) (Research).

Other Physiological Contexts Studied (If Applicable)

• Dietary cardiometabolic exposure: A cohort analysis in adults with type 2 diabetes found associations between dietary glutamine, dietary glutamate, cardiovascular disease incidence, and mortality, but observational design prevents causal interpretation (Research).
• Jejunal absorption physiology: Enteral glutamine administration was efficiently absorbed by the human jejunum in a controlled absorption study, making it relevant to physiological absorption rather than disease-outcome claims (Research).
• Protein-intake kinetics: Controlled dietary protein exposure altered glutamine and glutamate kinetic measurements in healthy young men, but this evidence reflects dietary protein physiology rather than isolated L-glutamine supplementation (Research).
• Parenteral nutrition context: Glutamine dipeptide-supplemented parenteral nutrition was studied for small-intestinal absorption capacity during critical illness, which places it in a clinical-nutrition context rather than ordinary oral intake (Research).

Safety, Interactions & Regulation

The phase 3 sickle cell disease trial is a primary human safety and efficacy source for pharmaceutical-grade L-glutamine in that population (Research). FDA approval materials provide product-specific regulatory safety context for L-glutamine oral powder in sickle cell disease (FDA).

A dosing and efficacy review reported that acute intakes around 20–30 g appeared without ill effect in available healthy adult human evidence, but this should not be generalized to all populations, disease states, or chronic use contexts (Review). Critical-illness safety and outcome interpretation is more cautious because a systematic review concluded that glutamine should not be routinely added for critically ill patients to reduce hospital mortality (Review).

The locked evidence library does not support broad supplement-drug interaction claims. A pediatric randomized sickle cell disease trial studied L-glutamine in children receiving stable hydroxyurea, which supports a studied combination context but not a universal interaction conclusion (Research).

In the United States, FDA approved L-glutamine oral powder, Endari, for reducing acute complications of sickle cell disease in adults and pediatric patients 5 years and older (FDA). FDA clinical pharmacology materials describe body-weight-based total daily doses of 10 g, 20 g, or 30 g divided into two doses in the reviewed product context (FDA).

In the European Union, EMA lists Xyndari, a glutamine medicine application for sickle cell disease, as withdrawn (EMA). EMA’s withdrawal assessment report describes Xyndari as intended for prevention of sickle cell crises in adults and children 5 years and older and includes a 10 g, 20 g, or 30 g total daily dose framework (EMA).

Evidence Overview

The overall human evidence base for L-glutamine is strongest in Blood Health for sickle cell disease, moderate but context-specific in Digestive and Gastrointestinal Health and Cancer Research supportive care, mixed in critical illness and burns, and limited in Muscle Health exercise recovery (Research) (Review) (Review) (Research). Confidence is not higher because studies use different populations, routes, formulations, dose ranges, treatment settings, and endpoints, including free L-glutamine, L-alanyl-L-glutamine, hydrolyzed protein, enteral nutrition, parenteral nutrition, IV delivery, and FDA-reviewed pharmaceutical oral powder (Research) (FDA).

In Blood Health, L-glutamine has unusually clear clinical and regulatory context because a phase 3 sickle cell disease trial and FDA approval both support a specific disease-specific oral powder use case (Research) (FDA). This evidence does not automatically support broader claims outside sickle cell disease because the FDA-reviewed product, population, and indication are specific (FDA).

Digestive and Gastrointestinal Health evidence includes randomized IBS trials and a systematic review/meta-analysis on intestinal permeability (Research) (Review). These studies support a gastrointestinal research signal, but the evidence varies by IBS subtype, diet context, permeability status, exposure form, and outcome measure (Research).

Cancer Research evidence mainly concerns oral mucositis, dysphagia, stomatitis, and treatment-related toxicity during chemotherapy or radiotherapy (Review) (Research). Meta-analyses report reduced mucositis risk or severity in some settings, but the evidence should be described as supportive-care research rather than cancer-treatment evidence (Review).

Critical illness and burns show the clearest cautionary pattern because individual studies may report infection-related signals while systematic reviews can be neutral or cautionary (Review) (Research). A 2024 burn-patient systematic review stated that routine glutamine supplementation for hospitalized burn patients was not recommended based on available data, while individual burn studies reported bacteremia-related findings (Review) (Research).

Formulation is a central limitation across the evidence base because free L-glutamine, L-alanyl-L-glutamine, hydrolyzed wheat protein, enteral glutamine, IV dipeptide delivery, and parenteral nutrition are not equivalent exposure contexts (Research) (Research). Future confidence would be strengthened by trials that use clearly defined populations, standardized formulations, consistent endpoints, and dose-exposure measures that connect plasma response with clinical outcomes (Research).

Evidence Confidence Classification

Moderate / Mixed is the overall human evidence classification for L-glutamine because strong evidence exists for one defined sickle cell disease indication, while other research areas show condition-specific, mixed, or limited findings (Research) (Review).

The Blood Health evidence is strongest because randomized sickle cell disease data and FDA review support a specific pharmaceutical oral powder context (Research) (FDA). Digestive and Gastrointestinal Health and Cancer Research evidence is moderate but narrower because studies focus on IBS, permeability, mucositis, dysphagia, or treatment-related supportive-care endpoints (Review) (Review). Muscle Health evidence is limited, and critical-illness evidence is mixed because reviews do not support broad routine use across all critically ill patients (Research) (Review).

Similar Ingredients & Comparators

Similar supplement-style ingredients:

• L-glutamic acid
• Essential amino acids
• Branched-chain amino acids
• Whey protein
• Hydrolyzed protein
• Collagen peptides
• L-arginine
• L-citrulline
• Creatine
• HMB
• N-acetylcysteine

Medical / pharma comparator categories:

• Sickle cell disease therapies
• Hydroxyurea therapy category
• Oncology supportive-care interventions
• Oral mucositis supportive-care products
• Enteral nutrition formulas
• Parenteral nutrition formulations
• Critical-care nutrition protocols
• Burn-care nutrition support

Combination Context

L-glutamine + low-FODMAP diet:
This combination was studied in IBS, where researchers evaluated glutamine added to a low-FODMAP diet rather than glutamine alone (Research). The study reported greater IBS symptom improvement in the combination context, but the result should not be separated from the dietary protocol (Research).

L-glutamine + hydroxyurea:
A pediatric sickle cell disease trial studied L-glutamine in children receiving stable hydroxyurea (Research). The trial reported reduced vaso-occlusive crises and possible favorable effects on cerebral arterial flow velocities, but the evidence is specific to that pediatric and treatment-background context (Research).

L-alanyl-L-glutamine as a dipeptide delivery format:
L-alanyl-L-glutamine, also written L-alanylglutamine or AlaGln, is a glutamine-containing dipeptide studied as a delivery format rather than free L-glutamine itself (Research). It has been studied in pharmacokinetic and oncology supportive-care contexts, including bolus versus intermittent exposure and IV chemoradiotherapy-associated mucositis research (Research) (Research). The main limitation is that dipeptide evidence should not be treated as identical to free oral L-glutamine evidence (Research).

Glutamine + enteral nutrition:
Enteral glutamine has been studied in human intestinal absorption and critical-care contexts (Research) (Review). The evidence is useful for absorption and clinical nutrition interpretation, but critical-illness outcomes remain mixed across reviews (Review).

Glutamine dipeptide + parenteral nutrition:
Glutamine dipeptide-supplemented parenteral nutrition has been studied for small-intestinal absorption capacity during critical illness (Research). This combination belongs to clinical nutrition and hospital-based research, not ordinary food or supplement exposure (Research).

FAQ

What is L-glutamine?

L-glutamine is an amino acid found in dietary protein and studied in humans as free oral L-glutamine, enteral glutamine, parenteral nutrition, glutamine-containing dipeptides, and pharmaceutical oral powder (Research) (FDA). Human research has examined L-glutamine in gastrointestinal, hematologic, oncology supportive-care, burn, critical-care, and exercise-recovery contexts (Research) (Research). The form studied matters because free L-glutamine, L-alanyl-L-glutamine, and protein-derived glutamine can produce different plasma response patterns (Research).

What is L-alanyl-L-glutamine?

L-alanyl-L-glutamine, also written L-alanylglutamine or AlaGln, is a glutamine-containing dipeptide studied as a delivery format for increasing L-glutamine exposure (Research). It is not the same molecule as free L-glutamine, and human absorption research shows that L-alanylglutamine can produce different plasma L-glutamine response patterns from free L-glutamine or hydrolyzed wheat protein (Research). L-alanyl-L-glutamine also appears in PK and IV oncology supportive-care research, so it should be described separately from oral free L-glutamine (Research) (Research).

What does human research study it for?

Human research studies L-glutamine for IBS-D, intestinal permeability, sickle cell disease complications, oral mucositis during cancer therapy, burn-related infection outcomes, critical-illness nutrition, and exercise recovery (Research) (Research) (Review). The research includes randomized trials, pharmacokinetic studies, dietary exposure analyses, clinical-nutrition studies, and systematic reviews or meta-analyses (Research) (Review). Findings should be interpreted by condition and formulation because the evidence differs across populations, routes, doses, and endpoints (Review).

What are the best-supported uses?

The best-supported use in the locked evidence base is Blood Health for sickle cell disease, where randomized clinical evidence and FDA approval support a defined L-glutamine oral powder product (Research) (FDA). Digestive and Gastrointestinal Health has supportive IBS and permeability evidence, but it is more population-specific and protocol-dependent (Research) (Review). Cancer Research has supportive-care evidence for mucositis and related treatment-toxicity outcomes, but it should not be described as cancer-treatment evidence (Review).

Where is evidence mixed or limited?

Evidence is mixed in critical illness because systematic reviews do not support routine glutamine addition for all critically ill patients to reduce hospital mortality (Review). Burn evidence is also mixed because individual trials report bacteremia-related signals while recent reviews caution against routine supplementation for hospitalized burn patients (Research) (Review). Muscle Health evidence is limited because the locked source base includes a short-term exercise-recovery trial rather than long-term performance, strength, or hypertrophy studies (Research).

How quickly does it act?

Oral and enteral glutamine can raise plasma L-glutamine in human absorption studies (Research) (Research). Peak timing can differ by formulation, including free L-glutamine, L-alanylglutamine, and hydrolyzed wheat protein (Research). Clinical outcomes in IBS, sickle cell disease, exercise recovery, and oncology supportive care were measured over hours, days, weeks, or treatment periods depending on the study design, not as a single universal onset time (Research) (Research).

What affects absorption and variability?

Absorption and variability are affected by route, formulation, dose, dosing pattern, disease state, population, and outcome selection (Research) (Research). A human absorption study showed different plasma response patterns after free L-glutamine, L-alanylglutamine, and hydrolyzed wheat protein (Research). Critical-care outcome variability also reflects patient severity, route, and study design differences (Review).

Is tolerance reported?

A clear tolerance pattern is not established in the locked L-glutamine evidence base. FDA materials and clinical studies provide dosing, safety, and outcome information rather than evidence of diminishing response over time (FDA). PK studies measured exposure and peak-concentration-related parameters, but those data do not establish a clinical tolerance model (Research).

Why do studies disagree?

Studies disagree because L-glutamine research uses different routes, formulations, doses, populations, and outcomes (Research). A sickle cell disease trial, an IBS-D trial, a mucositis trial, a burn study, and a critical-care meta-analysis each ask different research questions (Research) (Research) (Review). This is why evidence should be interpreted by condition and formulation rather than summarized as one universal L-glutamine effect (Review).

What ingredients is it commonly combined with and why?

L-glutamine has been studied with low-FODMAP diet therapy, stable hydroxyurea therapy, enteral nutrition, parenteral nutrition, and alanyl-glutamine dipeptide delivery formats (Research) (Research) (Research). These combinations were studied for specific research contexts such as IBS symptoms, pediatric sickle cell disease outcomes, absorption, clinical nutrition, and oncology supportive care (Research) (Research). The evidence does not support assuming that all combinations or glutamine-containing formulations have the same effects (Research).

What foods naturally contain this ingredient?

L-glutamine occurs as part of dietary protein, and human studies have examined glutamine-related exposure through diet or controlled dietary protein intake (Research) (Research). Dietary exposure differs from isolated L-glutamine powder because foods contain many amino acids and nutrients together (Research). The locked evidence base supports dietary-exposure context but does not provide a ranked food-source table (Research).

How is it regulated?

In the United States, FDA approved L-glutamine oral powder for reducing acute complications of sickle cell disease in adults and pediatric patients 5 years and older (FDA). FDA clinical pharmacology materials describe body-weight-based total daily doses of 10 g, 20 g, or 30 g divided into two doses in the reviewed product context (FDA). In the European Union, EMA lists Xyndari as withdrawn and describes the intended sickle cell disease prevention context in its withdrawal assessment report (EMA) (EMA).

Resources

• FDA approval summary for L-glutamine oral powder — FDA — https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-l-glutamine-powder-treatment-sickle-cell-disease
• FDA clinical pharmacology review for Endari — FDA — https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/208587Orig1s000ClinPharmR.pdf
• Xyndari EPAR page — EMA — https://www.ema.europa.eu/en/medicines/human/EPAR/xyndari
• Xyndari withdrawal assessment report — EMA — https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-xyndari_en.pdf
• Phase 3 sickle cell disease trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/30021096/
• Post-infectious IBS-D trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/30108163/
• Low-FODMAP plus glutamine IBS trial — PubMed — https://pubmed.ncbi.nlm.nih.gov/34977110/
• Oral mucositis systematic review/meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/33605813/
• Intestinal permeability systematic review/meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/39397201/
• Critical illness systematic review/meta-analysis — PubMed — https://pubmed.ncbi.nlm.nih.gov/33222464/
• Oral formulation absorption study — PubMed — https://pubmed.ncbi.nlm.nih.gov/22575040/
• Exercise recovery study — PubMed — https://pubmed.ncbi.nlm.nih.gov/25811544/

Image

Hero Image Description (CMS Use Only):
Create a 1344 × 768 px hero image with the text “L-Glutamine” in Helvetica. The scene should show a healthy human figure in a clean, natural, wellness-oriented environment. Do not include bottles, pills, capsules, powders, bowls, medical devices, or extra objects.

SEO Metadata Suggestions (CMS Use Only)

Meta description: